Silence Therapeutics (SLN) Stock Statistics & Valuation Metrics

Silence Therapeutics has a market cap or net worth of $258.37M. The enterprise value is $246.93M.

Silence Therapeutics has 47,233,948 shares outstanding. The number of shares has decreased by -2.65% in one year.

Silence Therapeutics’s return on equity (ROE) is -1.92 and return on invested capital (ROIC) is -76.23%.

The current PE Ratio of Silence Therapeutics is ―. Silence Therapeutics’s PEG ratio is 0.16.

In the last 12 months, Silence Therapeutics had revenue of 559.00K and earned -88.61M in profits. Earnings per share was -1.89.

In the last 12 months, operating cash flow was -62.27M and capital expenditures -110.00K, giving a free cash flow of -62.38M billion.

Silence Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Silence Therapeutics upcoming earnings date is May 20, 2026, TBA (Confirmed).

Silence Therapeutics as a current ratio of 8.72, with Debt / Equity ratio of -0.35%

In the past 12 months, Silence Therapeutics has paid 11.00K in taxes.

Silence Therapeutics EV to EBITDA ratio is -4.53, with an EV/FCF ratio of -4.42.

Silence Therapeutics has $85.11M in cash and marketable securities with -$160.00K in debt, giving a net cash position of $85.27M billion.

Gross margin is 61.54%, with operating margin of -16055.99%, and net profit margin of -15851.88%.

The average price target for Silence Therapeutics is $34.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy